Esperion Therapeutics Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Esperion Therapeutics de 66.1% y 31.1% respectivamente, mientras que el BPA crecerá en un 66.7% al año.

Información clave

66.1%

Tasa de crecimiento de los beneficios

66.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.8%
Tasa de crecimiento de los ingresos	31.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	19 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022

Jan 20

Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection

Oct 27

Esperion: Hunting Big Game In The Danger Zone

Aug 05

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:ESPR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	512	148	N/A	N/A	4
12/31/2025	428	88	142	58	6
12/31/2024	324	-59	93	28	7
9/30/2024	295	-87	-26	-26	N/A
6/30/2024	278	-98	-10	-10	N/A
3/31/2024	230	-87	-27	-27	N/A
12/31/2023	116	-209	-135	-135	N/A
9/30/2023	103	-208	-141	-141	N/A
6/30/2023	88	-222	-164	-164	N/A
3/31/2023	81	-239	-190	-190	N/A
12/31/2022	75	-234	-175	-175	N/A
9/30/2022	72	-243	-190	-190	N/A
6/30/2022	67	-258	-216	-216	N/A
3/31/2022	89	-235	-214	-214	N/A
12/31/2021	78	-269	-264	-264	N/A
9/30/2021	73	-308	-287	-275	N/A
6/30/2021	62	-325	-305	-292	N/A
3/31/2021	234	-156	-118	-105	N/A
12/31/2020	228	-144	-99	-85	N/A
9/30/2020	219	-101	-67	-67	N/A
6/30/2020	216	-84	-39	-38	N/A
3/31/2020	5	-263	-232	-231	N/A
12/31/2019	148	-97	-71	-70	N/A
9/30/2019	147	-95	-50	-49	N/A
6/30/2019	146	-77	-29	-29	N/A
3/31/2019	145	-68	-14	-14	N/A
12/31/2018	N/A	-202	-149	-149	N/A
9/30/2018	N/A	-180	-155	-155	N/A
6/30/2018	N/A	-175	N/A	-153	N/A
3/31/2018	N/A	-173	N/A	-140	N/A
12/31/2017	N/A	-167	N/A	-131	N/A
9/30/2017	N/A	-158	N/A	-113	N/A
6/30/2017	N/A	-130	N/A	-91	N/A
3/31/2017	N/A	-101	N/A	-72	N/A
12/31/2016	N/A	-75	N/A	-48	N/A
9/30/2016	N/A	-59	N/A	-40	N/A
6/30/2016	N/A	-55	N/A	-37	N/A
3/31/2016	N/A	-53	N/A	-39	N/A
12/31/2015	N/A	-50	N/A	-38	N/A
9/30/2015	N/A	-46	N/A	-38	N/A
6/30/2015	N/A	-43	N/A	-35	N/A
3/31/2015	N/A	-40	N/A	-32	N/A
12/31/2014	N/A	-36	N/A	-32	N/A
9/30/2014	N/A	-37	N/A	-31	N/A
6/30/2014	N/A	-32	N/A	-27	N/A
3/31/2014	N/A	-30	N/A	-25	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ESPR sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que ESPR sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ESPR sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (31.1% al año) de ESPR crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (31.1% al año) de ESPR crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ESPR se prevé que sea elevada dentro de 3 años.

Esperion Therapeutics Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to US$0.37 loss

Consensus revenue estimates fall by 12%

Price target decreased by 13% to US$7.41

Forecast breakeven date pushed back to 2025

Price target decreased by 18% to US$9.14

No longer forecast to breakeven

Recent updates

Esperion Highlights New Exploratory Data from Clear Outcomes Trial Highlighting Value of NEXLETOL (Bempedoic Acid) in Oral Featured Science Session and Multiple Poster Presentations At Aha Scientific Sessions 2024

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Esperion Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Esperion Therapeutics, Inc. Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe)

Esperion Therapeutics: Strategically Positioned To Grow

Esperion Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023)

Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Consensus EPS estimates upgraded to US$0.37 loss

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Consensus revenue estimates fall by 12%

Price target decreased by 13% to US$7.41

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million.

Esperion Is Sitting On A Potential Blockbuster Drug

Forecast breakeven date pushed back to 2025

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet

New major risk - Shareholder dilution

Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023

Price target decreased by 18% to US$9.14

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Consensus EPS estimates upgraded to US$1.99 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Forecast breakeven date moved forward to 2024

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023

Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet

Price target decreased by 10% to US$10.08

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 12% to US$12.22

Price target decreased by 11% to US$10.41

Consensus revenue estimates fall by 24%

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Consensus revenue estimates increase by 22%

Consensus revenue estimates fall by 20%

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Forecast to breakeven in 2024

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$12.10

Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Esperion Therapeutics Q2 2022 Earnings Preview

Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors